Combination therapy in hormone-refractory prostate cancer

被引：0
|
作者：
Daniel P. Petrylak
机构：
来源：
Current Oncology Reports | 2001年 / 3卷 / 5期
关键词：
Prostate Cancer; Hydrocortisone; Docetaxel; Mitoxantrone; Estramustine;
D O I：
10.1007/s11912-001-0033-4
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：453 / 453
相关论文
共 50 条
  • [31] The androgen receptor in hormone-refractory prostate cancer
    Mao, Hai-Lei
    Zhu, Zhi-Qi
    Chen, Charlie Degui
    ASIAN JOURNAL OF ANDROLOGY, 2009, 11 (01) : 68 - 73
  • [32] Docetaxel (Taxotere) in hormone-refractory prostate cancer
    Petrylak, DP
    SEMINARS IN ONCOLOGY, 2000, 27 (02) : 24 - 29
  • [33] Revolutions in the management of hormone-refractory prostate cancer
    Abrahamsson, PA
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 1 - 2
  • [34] Therapeutic options for hormone-refractory prostate cancer
    Miller, K.
    Boergermann, C.
    Thueroff, J.
    Albers, P.
    Wirth, M.
    UROLOGE, 2006, 45 (05): : 580 - +
  • [35] Paclitaxel in the treatment of hormone-refractory prostate cancer
    Smith, DC
    Pienta, KJ
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 109 - 111
  • [36] Treatment options for hormone-refractory prostate cancer
    Heidenreich, A
    Ohlmann, CH
    UROLOGE, 2005, 44 (11): : 1303 - +
  • [37] Hormone-refractory prostate cancer: Therapeutic approach
    Pepe, A.
    Leonardi, V.
    Palmisano, V.
    Savio, G.
    Calabria, C.
    Laudani, A.
    Usset, A.
    Cusimano, M.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 155
  • [38] Satraplatin in the treatment of hormone-refractory prostate cancer
    Sternberg, CN
    BJU INTERNATIONAL, 2005, 96 (07) : 990 - 994
  • [39] The role of bisphosphonates in hormone-refractory prostate cancer
    Fred Saad
    Pierre Karakiewicz
    Paul Perrotte
    World Journal of Urology, 2005, 23 : 14 - 18
  • [40] DocetaxelIn Hormone-Refractory Metastatic Prostate Cancer
    Kate McKeage
    Susan J. Keam
    Drugs, 2005, 65 : 2287 - 2294
12345